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Transformed cells have been documented to be methionine-dependent, suggesting that inhibition of methionine synthesis
might be useful for cancer therapy. Methylenetetrahydrofolate reductase synthesises 5-methyltetrahydrofolate, the methyl
donor utilised in methionine synthesis from homocysteine by vitamin B12-dependent methionine synthase. We hypothesised
that methylenetetrahydrofolate reductase inhibition would affect cell viability through decreased methionine synthesis. Using
medium lacking methionine, but containing homocysteine and vitamin B12 (M-H+), we found that nontransformed human
ﬁbroblasts could maintain growth. In contrast, four transformed cell lines (one colon carcinoma, two neuroblastoma and one
breast carcinoma) increased proliferation only slightly in the M-H+ medium. To downregulate methylenetetrahydrofolate
reductase expression, two phosphorothioate antisense oligonucleotides, EX5 and 677T, were used to target
methylenetetrahydrofolate reductase in the colon carcinoma line SW620; 400 nM of each antisense oligonucleotide
decreased cell survival by approximately 80% (P50.01) and 70% (P50.0001), respectively, compared to cell survival after the
respective control mismatched oligonucleotide. Western blotting and enzyme assays conﬁrmed that methylenetetrahydrofolate
reductase expression was decreased. Two neuroblastoma and two breast carcinoma lines also demonstrated decreased
survival following EX5 treatment whereas nontransformed human ﬁbroblasts were not affected. This study suggests that
methylenetetrahydrofolate reductase may be required for tumour cell survival and that methylenetetrahydrofolate reductase
inhibition should be considered for anti-tumour therapy.
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Folate derivatives participate in single-carbon transfers in several
reactions, including the synthesis of nucleotides and methionine.
Methionine is the precursor of S-adenosylmethionine which is
utilised in numerous transmethylation reactions, including DNA
methylation. Methylenetetrahydrofolate reductase (MTHFR)
converts 5,10-methylenetetrahydrofolate, the methyl donor in
thymidine synthesis, into 5-methyltetrahydrofolate, the predomi-
nant circulatory form of folate. 5-Methyltetrahydrofolate is a co-
substrate for homocysteine remethylation to methionine by the
vitamin B12-dependent methionine synthase. Consequently,
MTHFR maintains the balance between folates utilised in DNA
synthesis and folates utilised in the methionine cycle/DNA methy-
lation. A common variant in MTHFR, an alanine to valine
substitution in exon 4, 677C?T (Goyette et al, 1994; Frosst et
al, 1995), has been implicated in many complex disorders. This
polymorphism, which is present in the homozygous state in 5–
20% of North Americans and Europeans, has been reported to
decrease risk of colon cancer (Ma et al, 1997) and adult lympho-
cytic leukaemia (Skibola et al, 1999). Homozygosity is associated
with a mild enzymatic deﬁciency (approximately 40% of control
values) (Frosst et al, 1995).
Identiﬁcation of biochemical differences between normal and
transformed cells may aid in the treatment of human cancers.
Methionine auxotrophy of transformed cells is one such biochem-
ical change. This methionine dependence may be due to the high
methionine requirement for transmethylation reactions resulting
in low free-methionine levels and low S-adenosylmethionine/S-
adenosylhomocysteine ratios (Coalson et al, 1982; Guo et al,
1993a). Many tumour-derived cell lines show sensitivity to a
limited methionine supply and arrest in late-S/G2 stage of the cell
cycle in vitro and in vivo (Guo et al, 1993a,b; Hoffman and Jacob-
sen, 1980).
This study examined methionine dependence in nontransformed
ﬁbroblasts and in several transformed lines (one colon carcinoma,
two neuroblastoma, one breast carcinoma). In a second series of
experiments, we downregulated MTHFR, due to its role in methio-
nine synthesis, by transfection of antisense oligonucleotides (ASOs)
in order to evaluate survival of the transformed cells. Antisense
technology has been successfully employed to downregulate the
expression of numerous genes in tumour cells (Crooke, 1992).
These ASOs can inhibit gene expression by forming RNA-DNA
duplexes resulting in a decrease in the target gene products
(Zamecnik, 1996). Data presented in this study demonstrate that
antisense-mediated reduction of MTHFR expression is associated
with a substantial decrease in cell viability of transformed cells.
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Cell lines
Human ﬁbroblasts MCH 51 and MCH 75 were obtained from the
Repository for Mutant Human Cell Strains (Montreal Children’s
Hospital, Montreal, Canada). Human colon carcinoma cell line
SW620 and two neuroblastoma lines (BE(2)C and SKNF-1) were
obtained from American Type Culture Collection (Rockville,
MD, USA). The breast carcinoma cell lines, MCF7 and SKBr3, were
a gift from Dr Morag Park (McGill University, Montreal, Canada).
Genotyping for the MTHFR variant at bp 677 was performed by
PCR ampliﬁcation and HinfI digestion, as previously reported
(Frosst et al, 1995). The MCF7 cell line was grown in a-minimal
essential medium (a-MEM) (Life Technologies, Rockville, MD,
USA) and the SKBr3 cell line was maintained in D-MEM (Life
Technologies). Media for both lines was supplemented with 10%
foetal bovine serum (Intergen, Purchase, NY, USA). The other cell
lines were grown in MEM (Life Technologies) supplemented with
5% foetal bovine serum (Intergen) and 5% iron enriched calf
serum (Intergen).
All media was also supplemented with 50 IU ml
71 penicillin
(Life Technologies), 50 mgm l
71 streptomycin (Life Technologies),
0.5 mgm l
71 fungizone reagent (Life Technologies). All cell lines
were cultured in 75 cm
2 ﬂasks in a humidiﬁed 378C incubator in
5% CO2.
Deﬁcient culture media
MEM and MEM without folate and methionine supplemented with
100 mM sodium pyruvate (F-M-) were obtained from Life Tech-
nologies. For methionine-deﬁcient (M-) media, 2.3 mM folate
(Sigma-Aldrich, Oakville, ON, USA) was added to the F-M- media.
For all media, 5% foetal bovine serum (Intergen), 5% iron
enriched calf serum (Intergen), 50 IU ml
71 penicillin (Life Tech-
nologies), 50 mgm l
71 streptomycin (Life Technologies), and
0.5 mgm l
71 fungizone reagent (Life Technologies) were added.
For methionone-deﬁcient medium supplemented with homocys-
teine and vitamin B12 (M-H+) media, 0.44 mm DL-homocysteine
(Sigma-Aldrich) and 1.5 mM vitamin B12 (Sigma-Aldrich) was
added to the M- media. Dialysed serum was used for all experi-
ments with deﬁcient media. These conditions were based on
similar studies in ﬁbroblasts and in transformed lines (Hoffman
and Erbe, 1976; Rosenblatt and Erbe, 1977).
Cell survival studies of cells in deﬁcient media
Cell viability studies were performed in 6-well tissue culture plates
starting with 30000–50000 cells per well and three replicates for
each condition. The initial number of cells were estimated with a
hemocytometer. Cell survival in MEM was used as a control for
proliferation in deﬁcient media (M-, M-H+). Surviving cells were
counted using the FluoroReporter Colorimetric Cell Protein Assay
Kit (Molecular Probes, Eugene, OR, USA).
Phosphorothioate oligonucleotides
Oligonucleotides (20 bp) with phosphorothioate backbones were
obtained from Synthetic Genetics (San Diego, CA, USA) dissolved
in 16Tris-EDTA pH 7.4. The oligonucleotides in this study were:
EX5 (targets nucleotides 796–815 in exon 5 of the human MTHFR
mRNA sequence), sequence 5'-AGC TGC CGA AGG GAG TGG
TA-3'; CTSEX5 (control oligonucleotide, scrambled version of
EX5 with the same base composition but a randomised sequence);
677T (targeting nucleotides 668–687 in exon 4 of the human
MTHFR mRNA with valine as the polymorphic codon), sequence
5'-GAT GAA ATC GAC TCC CGC AG-3'; 677C (1 bp mismatch
control sequence targeting the alanine allele of human MTHFR),
sequence 5'-GAT GAA ATC GGC TCC CGC AG-3'; CT677
(control oligonucleotide which has six mismatches compared to
the sequence of 677T), sequence 5'-AAC GAT AGC GTC TCC
CGC AT-3'. The sequences of CT677 and CTSEX5 did not show
homology to any known human genes in a BLAST search.
Transfection with oligonucleotides and cell counting
Cells were plated in 6-well dishes at 50–70% conﬂuence and
incubated overnight in complete medium (Life Technologies).
Each well was washed once with OPTI-MEM I (Life Technolo-
gies). The cells were then overlaid with 1 ml of Opti-MEM I
media containing 12 mgm l
71 Lipofectin reagent (Life Technolo-
gies) per 400 nM of oligonucleotide. The media was replaced
with complete media (2–4 ml) after 5 h incubation at 378C with
the ASOs. Transfection with oligonucleotides was performed on 3
consecutive days followed by a 3-day period of regrowth in
MEM. Cells were counted by SRB staining as outlined in the
FluoroReporter Colorimetric Cell Protein Assay Kit (Molecular
Probes). In each experiment, treatments were performed in tripli-
cate.
In dose response experiments, the total oligonucleotide concen-
tration was held constant at 400 nM by supplementing the tested
oligonucleotide with the control oligonucleotide (Basilion et al,
1999).
Protein extraction after treatment with oligonucleotides
For Western blot analysis and MTHFR enzyme assays, 6610
5
SW620 colon carcinoma cells were plated in 100 mm tissue culture
treated petri dishes. After transfection of cells with oligonucleo-
tides, the cells were harvested, and crude protein extracts from
cell pellets were obtained by freezing the pellet at 7708C and
thawing to 48C three successive times. The cell pellet was then
resuspended in 0.1 M KPO4 pH 6.3 with 2 mgm l
71 aprotinin
(Boehringer Mannheim, Laval, Quebec, Canada) and 2 mgm l
71
leupeptin (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Cellular debris was cleared by centrifugation at 14000 r.p.m. for
10 min. Protein concentration was assayed using the Bradford
method (Bradford, 1976) according to the manufacturer’s instruc-
tions (BioRad, Mississauga, ON, USA).
MTHFR enzyme assay
Enzyme activity was measured in the reverse direction, in crude
protein extracts, as previously described (Christensen et al, 1997).
Equal amounts of protein (*60 mg) were used per assay. Enzyme
activity was expressed as nmol formaldehyde formed per mg
protein h
71.
Western blot analysis
Equal amounts of protein (35–60 mg) were loaded onto a 10%
SDS polyacrylamide gel. Transfer was performed in a transfer
buffer (39 mM glycine, 49 mM Tris base, 0.037% SDS, 20% metha-
nol) for 2–3 h at 70 V to nitrocellulose (Hybond ECL membrane,
Amersham Pharmacia Biotech). The membrane was blocked with
5% non-fat skim milk in PBS-0.5% Tween 20 (Tween 20; BioRad)
overnight at 48C and then cut for separate incubations with anti-
bodies against MTHFR and actin. The MTHFR protein was
detected using a rabbit anti-porcine MTHFR antibody
(previously-utilised in Frosst et al, 1995) at a dilution of 1:1000
in 5% non-fat skim milk in PBS-0.5% Tween 20 incubated for
4–6 h at 48C. The actin antibody was utilised according to the
instructions of the supplier (Amersham Pharmacia Biotech). After
three successive washes in PBS-0.5% Tween 20, anti-rabbit horse-
radish peroxidase-conjugated antibody (Amersham Pharmacia
Biotech) was used as a secondary antibody. The immunocomplexes
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(Amersham Pharmacia Biotech). Quantitation of protein was
determined by scanning the ﬁlms with a ﬂat-bed scanner (Hewlett
Packard Scan). MTHFR has been shown to have two isoforms
(Frosst et al, 1995). Both MTHFR bands and the actin band areas
were calculated; MTHFR protein level is expressed as a ratio of
MTHFR/actin.
Statistical analysis
One-way ANOVA was performed using SPSS software, Version
10.0 (SPSS Inc., Chicago, IL, USA), to analyse cell survival after
treatment with EX5. Statistical analysis of cell survival data of
SW620 cells following treatment with 677T was performed with
the SAS-PC statistical software, Version 8.0 (SAS Institute, Cary,
NC, USA). The mixed effects analysis of variance model was used.
In this model two factors were considered: drug and concentration.
The Student t-test was used to evaluate differences in MTHFR
activity, and to analyse cell survival data of ﬁbroblast cell lines trea-
ted with EX5, 677C and 677T antisense.
RESULTS
Growth studies in methionine-deﬁcient media
Two ﬁbroblast strains (Figure 1) and 4 transformed lines (Figure 2)
were grown in MEM, MEM without methionine (M-), or MEM
without methionine supplemented with homocysteine and vitamin
B12 (M-H+). The latter medium served to examine de novo synth-
esis of methionine from homocysteine and 5-methyltetra-
hydrofolate, catalysed by vitamin B12-dependent methionine
synthase. 5-Methyltetrahydrofolate is the product of the MTHFR
reaction. All six lines showed sensitivity to the M- medium; growth
was signiﬁcantly reduced in this medium compared to that in
MEM. The ﬁbroblasts (MCH 51, MCH 75) could maintain
virtually normal growth in the M-H+ medium. However, the
transformed lines (colon carcinoma SW620, breast carcinoma
SKBr3 and neuroblastomas BE(2)C and SKNF-1) cultured in the
M-H+ medium increased their proliferation only slightly through
endogenous methionine synthesis (Figure 2). The cell numbers
were just a small percentage (5–25%) of the values obtained in
MEM. The SKBr3 line was also tested with a lower concentration
of homocysteine in the M-H+ medium (0.2 mM DL-homocys-
teine); the results were similar to those with the higher
concentration (0.44 mM) (data not shown).
Treatment with the EX5 antisense
A BLAST search identiﬁed sequences in exon 5 of MTHFR that did
not have any homology with other ESTs in the NCBI database.
Figure 3a demonstrates a dose-dependent decrease in cell survival
(P50.01, one-way ANOVA) after treatment of SW620 carcinoma
cells with EX5. At the maximal dose of 400 nM, cell survival
decreased approximately 80% compared to that of cells treated
with the scrambled control oligonucleotide.
To ensure that MTHFR expression was altered, Western blot-
ting was used to analyse immunoreactive MTHFR protein, after
three consecutive treatments with the EX5 ASO. In previous
work, we showed that two MTHFR isoforms are present in
human tissues (Frosst et al, 1995); these isoforms differ only at
the N-terminus of the protein encoded by the 5' end of the
mRNA. Consequently, the antisense should inhibit expression of
both isoforms. Figure 3b demonstrates a signiﬁcant decrease in
MTHFR protein levels after EX5 treatment, compared to treat-
ment with the scrambled control, CTSEX5, or compared to
treatment with Lipofectin reagent only (mock transfection). After
normalisation to actin, MTHFR protein levels following treatment
with the control oligo were 94% of mock-treated cells, whereas
treatment with 200 and 400 nM of EX5 oligo, MTHFR protein
levels were 39% and 25%, respectively, of that in mock-treated
cells (average of three Western blots).
After treatment with 400 nM of EX5, the two neuroblastoma cell
lines (BE(2)C and SKNF-1) showed signiﬁcant decreases in cell
survival compared to control ASO treated cells: decreases of 80%
(P50.001) and 65% (P50.01), respectively (data not shown).
Similarly, the breast carcinoma cell lines SKBr3 showed a 80%
(P50.0001) decrease in cell survival and the MCF7 breast carcino-
ma line showed a 92% (P50.0001) reduction in cell survival
compared to control oligo treated cells (data not shown). Contrary
to data obtained in transformed lines, two human ﬁbroblast cell
lines (MCH 75 and MCH 51) treated with 400 nM of EX5 did
not exhibit signiﬁcant differences in cell survival compared to
control oligo treated cells (P40.05; data not shown).
Treatment with the 677T antisense
A second oligonucleotide was chosen to target a different region of
the mRNA – exon 4, which is the location of the common variant
of MTHFR at bp 677. The SW620 line carries the valine allele with
a T at bp 677. The 677T antisense should target the valine allele in
SW620 whereas the 677C antisense, with one mismatch, should be
less effective. The control oligonucleotide, CT677, has a 6 bp
mismatch compared to the experimental oligonucleotide.
The cell survival of SW620 colon carcinoma cells treated with
677T differs signiﬁcantly from cells treated with the mismatched
control, CT677, at all four tested concentrations between 100 and
400 nM (P50.02 for 100 nM, P50.0001 for 200–400 nM) (Figure
4a). Cell survival decreased in a dose-dependent manner. At the
highest concentration, 400 nM, cell survival was approximately
70% less than that of cells treated with CT677.
Cell survival after transfection with the 677C oligonucleotide,
which differs from 677T by a single mismatch, was signiﬁcantly
higher at concentrations of 200–400 nM (P50.01) than that seen
with the 677T ASO (Figure 4a). At a concentration of 100 nM,
cell survival does not differ signiﬁcantly between 677C and
677T treated cells (P40.05). Cell survival after treatment with
677C is not signiﬁcantly different from cells treated with the
control CT677 at concentrations of 100 and 200 nM (P40.05),
and shows only small but borderline signiﬁcant differences at
300 and 400 nM (P=0.05 and P=0.04, respectively). At the maxi-
mal dose of 400 nM, cell survival after 677T transfection is
decreased by 70% compared to cells treated with the control
ASO, whereas survival after 677C transfection was decreased by
only 30%.
Western blotting (Figure 4b) demonstrated that MTHFR protein
levels were reduced following a 24-h transfection with the 677T
oligonucleotide. MTHFR protein levels following transfection of
the 677C or 677T were 81% and 17%, respectively, of the values
obtained in cells treated with the control CT677 oligo. In addition,
we measured enzyme activity after 24 h of treatment with Lipofec-
tin only (mock treatment), cells treated with 400 nM CT677
(control), and cells treated with 400 nM of 677C or 677T (data
not shown). Treatment with 400 nM of 677T reduced MTHFR
enzymatic activity signiﬁcantly (P50.01) compared to mock treat-
ment, to values that were approximately 20% (data not shown).
Treatment with 400 nM of the CT677 or 400 nM of the 677C
ASO, with the 1 bp mismatch to 677T, shows a borderline signiﬁ-
cant difference in enzymatic activity compared to mock treated
cells (P=0.02), but the decrease was minimal (86% of mock activ-
ity).
One ﬁbroblast cell line (MCH 75) was used to test the effect of
treatment with either 677C or 677T on normal methionine-inde-
pendent cells. This line is heterozygous for the polymorphism at
bp 677. Treatment of MCH 75 cells with either 677C or 677T does
not signiﬁcantly affect cell survival compared to control ASO trea-
ted cells (P40.05, data not shown).
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Antisense targeting of MTHFR in cancer cells
J Sekhon et al
227
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 225–230DISCUSSION
This study demonstrates, in vitro, the potential of using antisense
technology directed against MTHFR to decrease the cell viability
of methionine-dependent transformed cells. The analysis of cell
survival of nontransformed ﬁbroblasts and of several transformed
lines cultured in methionine-deﬁcient medium, with and without
homocysteine/vitamin B12 supplementation, supports earlier
reports of the high methionine requirement of transformed lines
(Hoffman, 1984); in that review, 23 human lines and 19 animal cell
lines were reported to be methionine-dependent. Although normal
ﬁbroblast lines showed the ability to restore their growth by restor-
ing endogenous methionine synthesis, the transformed cell lines
only exhibited a slight increase in survival under the same condi-
tions. The amount of recovery may in fact be a reﬂection of the
degree of transformation of the colon carcinoma lines (Breillout
et al, 1990).
By utilising antisense phosphorothioate deoxyoligonucleotides,
in vitro, to speciﬁcally suppress the expression of MTHFR, the cell
viability of a methionine-dependent colon carcinoma line was
substantially decreased. 677T was able to decrease cell survival by
70% at the maximal dose of 400 nM, while EX5 decreased cell
survival by 80% under similar conditions. The 677T ASO appears
to exhibit a high speciﬁcity for the valine form of MTHFR present
in SW620 cells; the 677C ASO, with only a single mismatch (at the
polymorphic nucleotide), did not have as great an effect on cell
survival. The differences in cell survival between the 677T and
677C oligos were signiﬁcantly different for concentrations of 200,
300 and 400 nM. These results are consistent with previous reports
demonstrating the speciﬁcity for one form of a target gene using
phosphorothioate oligonucleotides with single base mismatches as
controls (Duroux et al, 1995; Bennet et al, 1996; Basilion et al,
1999). Our observations also suggest that allele-speciﬁc targeting
may be possible for MTHFR. This approach has been proposed
as a method for targeting tumour tissues, which often undergo loss
of heterozygosity (LOH), without signiﬁcantly compromising the
gene and its product in non-tumour cells (Basilion et al, 1999).
For genes that have a common variant and are essential for cell
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Figure 1 Growth of ﬁbroblast cell lines in deﬁcient media. Two ﬁbroblast cell lines (MCH 51, MCH 75) were grown in MEM (&), M- (6), and M-H+
(*) for 12 days. The number of cells for each line was counted using the SRB assay at three time points. Each point represents the mean of three repli-
cates+s.d.
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Figure 2 Growth of transformed cell lines in deﬁcient media. The colon carcinoma cell line, SW620, was grown in MEM (&), M- (6), and M-H+ (*) for
12 days. The number of cells was counted using the Sulfarhodamine B (SRB) assay at three time points. Each point represents the mean of three replica-
tes+s.d. The same experiment was performed for a breast carcinoma line (SKBr3) and two neuroblastoma lines (BE(2)C and SKNF-1), except that the cells
were grown for 8 days and each point represents the mean of duplicates.
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tumour cells that have undergone LOH, whereas the non-tumour
tissue, with two alleles, should still retain the activity of the non-
targeted allele and, consequently, remain viable. We have recently
demonstrated that MTHFR undergoes 15–20% LOH in colorectal
tumours (Pereira et al, 1999); LOH for MTHFR may be as high as
45–50% in ovarian tumours (Viel et al, 1997).
Treatment of two neuroblastoma cell lines and two breast carci-
noma cell lines showed signiﬁcant decreases in cell survival after
treatment with 400 nM of EX5 compared to control oligo treated
cells. These results point to the applicability of downregulating
MTHFR expression in various types of tumour lines in order to
decrease cell survival. To test the effects of targeting MTHFR in
nontransformed cells, two human ﬁbroblast cell lines (MCH 75
and MCH 51) were treated. Both cell lines did not show signiﬁcant
changes in cell survival after treatment with 400 nM of EX5,
compared to control ASO treated cells. Similarly, treatment of
the MCH 75 ﬁbroblast line with 677T or 677C did not signiﬁcantly
affect cell survival, compared to CT677 treated cells. These results
suggest that antisense inhibition of MTHFR may have a more dele-
terious effect on methionine-dependent tumour cells.
The downregulation of MTHFR in methionine-dependent
tumour lines may cause decreases in methionine levels to an extent
that signiﬁcantly affects cell survival. The same decreases in
methionine production in methionine-independent lines may not
substantially affect cell survival since these cell lines are not reliant
on such high levels of methionine to sustain cell growth.
ASOs are designed to affect the information transfer from gene
to protein, by altering the metabolism of RNA (Crooke, 1999).
The end result is expected to be a decrease in levels of the gene
product. We therefore examined MTHFR protein levels after
antisense treatment. For the EX5 experiments, we performed
Western blotting under the same conditions that were used for
analysis of cell numbers i.e. following three rounds of transfec-
tion. For the 677T experiments, we found that the nonspeciﬁc
toxicity of the phosphorothioate oligonucleotides was quite high;
the toxicity of these oligos has been well documented (Stein and
Cheng, 1993; Stein, 1999). Due to the greater toxicity of the 677
oligos (control and experimental ASOs), cell survival was consid-
erably reduced after three rounds of transfection, even though
the speciﬁc oligo was always associated with lower cell numbers
than the control oligo. Consequently, we used one 24-h transfec-
tion, rather than three consecutive transfections, to generate
enough cells for Western blotting. The conclusions from both
sets of Westerns (EX5 and 677T oligos) were similar – MTHFR
protein was signiﬁcantly reduced compared to that of the control
oligonucleotides at the studied concentration (400 nM). MTHFR
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Figure 3 Cell survival and MTHFR protein levels after treatment with
the antisense oligonucleotide EX5. (A) Colon carcinoma SW620 cells were
treated on three successive days with increasing concentration of EX5.
Cells were also treated with a control ASO, CTSEX5. The number of sur-
viving cells was determined by SRB staining. Cell survival after transfection
with EX5 is expressed as a % of survival after transfection with the control
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harvested after the third treatment and subjected to Western blot analysis.
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Figure 4 Cell survival and MTHFR protein levels after treatment with
the antisense oligonucleotide 677T. (A) SW620 cells were treated on 3
successive days with increasing concentrations of 677T (&) or 677C
(*). 677C has a single mismatch compared to 677T, at the polymorphic
sequence in exon 4. The control oligonucleotide, CT677, contains six mis-
matches to the 677T sequence. The number of surviving cells was deter-
mined by SRB staining. Cell survival after transfection of 677T or 677C is
expressed as a percentage of the value obtained with the control CT677
oligonucleotide. Each value on the graph represents the mean+s.e. for ﬁve
experiments, each performed in triplicate. (B) SW620 cells were treated
with 400 nM of CT677, 400 nM of 677C, or 400 nM of 677T. Cells were
harvested after 24 h of treatment and subjected to Western blot analysis.
The position of the MTHFR protein and of the molecular weight markers is
indicated. Protein levels of b-actin were also assayed by Western blotting
to verify equal loading of samples.
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tion; this experiment demonstrated that the 677T oligo had a
direct effect on MTHFR activity.
Though reducing MTHFR expression to decrease cancer cell
survival is a novel hypothesis, other groups have successfully used
different means to decrease methionine availability for transformed
cells. Guo et al (1993a) deprived Yoshida sarcoma-bearing nude
mice of dietary methionine resulting in tumour regression and
extended survival of the mice. Other investigators have used the
enzyme methioninase in vivo (Tan et al, 1996a); this enzyme from
Pseudomonas putida catalyses the conversion of methionine to
methanethiol (Weimer et al, 1999). It has been shown to deplete
circulating methionine levels in mice and in humans (Lishko et
al, 1993; Tan et al, 1996b). In vivo studies injecting puriﬁed
methioninase into nude mice bearing either rodent or human
tumours have successfully arrested the growth of these methio-
nine-dependent tumours with no apparent toxic side effects (Tan
et al, 1996a).
This study has shown that a reduction in MTHFR levels reduces
cell viability in vitro. To evaluate the validity of this approach for
chemotherapy, these techniques need to be transferred to an in vivo
model. Inhibition of MTHFR through antisense technology or
through other means, such as pharmaceutical agents, should be
considered alone or in conjunction with other antifolate
compounds, such as methotrexate or 5-ﬂuorouracil, to increase
our arsenal of chemotherapeutic reagents.
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